Mainz Biomed (MYNZ) Competitors

$3.33 -0.23 (-6.46%)

As of 05/22/2026

MYNZ vs. EQ, CYPH, KLRS, AIFC, and RANI

Should you buy Mainz Biomed stock or one of its competitors? MarketBeat compares Mainz Biomed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mainz Biomed include Equillium (EQ), Cypherpunk Technologies (CYPH), Kalaris Therapeutics (KLRS), ALT5 Sigma (AIFC), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical products" industry.

How does Mainz Biomed compare to Equillium?

Equillium (NASDAQ:EQ) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

Mainz Biomed has lower revenue, but higher earnings than Equillium. Equillium is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	3.48	-$22.40M	-$0.32	N/A
Mainz Biomed	$659.94K	45.72	-$21.65M	-$65.60	N/A

Equillium has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat Equillium's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Mainz Biomed	N/A	N/A	N/A

Equillium presently has a consensus target price of $7.67, suggesting a potential upside of 239.23%. Given Equillium's stronger consensus rating and higher possible upside, analysts plainly believe Equillium is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Equillium had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Equillium and 0 mentions for Mainz Biomed. Equillium's average media sentiment score of 0.00 equaled Mainz Biomed'saverage media sentiment score.

Company	Overall Sentiment
Equillium	Neutral
Mainz Biomed	Neutral

27.1% of Equillium shares are owned by institutional investors. 17.8% of Equillium shares are owned by company insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Equillium beats Mainz Biomed on 9 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

In the previous week, Cypherpunk Technologies' average media sentiment score of 0.00 equaled Mainz Biomed'saverage media sentiment score.

Company	Overall Sentiment
Cypherpunk Technologies	Neutral
Mainz Biomed	Neutral

30.5% of Cypherpunk Technologies shares are held by institutional investors. 3.5% of Cypherpunk Technologies shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cypherpunk Technologies has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Cypherpunk Technologies has higher earnings, but lower revenue than Mainz Biomed. Cypherpunk Technologies is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Mainz Biomed	$659.94K	45.72	-$21.65M	-$65.60	N/A

Mainz Biomed's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Mainz Biomed	N/A	N/A	N/A

Summary

Mainz Biomed beats Cypherpunk Technologies on 7 of the 10 factors compared between the two stocks.

How does Mainz Biomed compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Kalaris Therapeutics had 6 more articles in the media than Mainz Biomed. MarketBeat recorded 6 mentions for Kalaris Therapeutics and 0 mentions for Mainz Biomed. Kalaris Therapeutics' average media sentiment score of 0.70 beat Mainz Biomed's score of 0.00 indicating that Kalaris Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Kalaris Therapeutics	Positive
Mainz Biomed	Neutral

Kalaris Therapeutics has a beta of 0.15, meaning that its stock price is 85% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

66.1% of Kalaris Therapeutics shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kalaris Therapeutics presently has a consensus target price of $15.60, suggesting a potential upside of 217.07%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kalaris Therapeutics is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Mainz Biomed has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Mainz Biomed	$659.94K	45.72	-$21.65M	-$65.60	N/A

Mainz Biomed's return on equity of 0.00% beat Kalaris Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Mainz Biomed	N/A	N/A	N/A

Summary

Kalaris Therapeutics beats Mainz Biomed on 9 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to ALT5 Sigma?

Mainz Biomed (NASDAQ:MYNZ) and ALT5 Sigma (NASDAQ:AIFC) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, ALT5 Sigma has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
ALT5 Sigma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Mainz Biomed has higher earnings, but lower revenue than ALT5 Sigma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	45.72	-$21.65M	-$65.60	N/A
ALT5 Sigma	$24.84M	5.03	-$344.51M	N/A	N/A

Mainz Biomed has a net margin of 0.00% compared to ALT5 Sigma's net margin of -2,483.94%. Mainz Biomed's return on equity of 0.00% beat ALT5 Sigma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
ALT5 Sigma	-2,483.94%	-68.25%	-62.43%

In the previous week, Mainz Biomed's average media sentiment score of 0.00 beat ALT5 Sigma's score of -0.47 indicating that Mainz Biomed is being referred to more favorably in the media.

Company	Overall Sentiment
Mainz Biomed	Neutral
ALT5 Sigma	Neutral

6.3% of ALT5 Sigma shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by company insiders. Comparatively, 0.2% of ALT5 Sigma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Mainz Biomed beats ALT5 Sigma on 8 of the 11 factors compared between the two stocks.

How does Mainz Biomed compare to Rani Therapeutics?

Mainz Biomed (NASDAQ:MYNZ) and Rani Therapeutics (NASDAQ:RANI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

Mainz Biomed's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Rani Therapeutics	N/A	-206.46%	-83.95%

In the previous week, Rani Therapeutics had 2 more articles in the media than Mainz Biomed. MarketBeat recorded 2 mentions for Rani Therapeutics and 0 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.00 equaled Rani Therapeutics'average media sentiment score.

Company	Overall Sentiment
Mainz Biomed	Neutral
Rani Therapeutics	Neutral

Mainz Biomed has higher earnings, but lower revenue than Rani Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	45.72	-$21.65M	-$65.60	N/A
Rani Therapeutics	$1.63M	81.20	-$29.67M	-$0.41	N/A

Rani Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 717.76%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

30.2% of Rani Therapeutics shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Rani Therapeutics beats Mainz Biomed on 10 of the 14 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYNZ vs. The Competition

Export

Metric	Mainz Biomed	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.17M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.05	18.74	20.99	25.66
Price / Sales	45.72	323.98	560.30	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	1.28	7.09	10.41	7.14
Net Income	-$21.65M	$24.45M	$3.57B	$335.98M
7 Day Performance	0.91%	6.38%	6.41%	4.15%
1 Month Performance	556.03%	2.43%	3.55%	2.54%
1 Year Performance	58.57%	62.98%	34.12%	35.06%

Mainz Biomed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYNZ Mainz Biomed	N/A	$3.33 -6.5%	N/A	+58.6%	$30.17M	$659.94K	N/A	30	Gap Up High Trading Volume
EQ Equillium	2.0292 of 5 stars	$1.89 +2.4%	$7.67 +306.7%	+456.7%	$119.19M	$41.10M	N/A	40
CYPH Cypherpunk Technologies	0.2025 of 5 stars	$1.11 +6.3%	N/A	+229.1%	$117.69M	N/A	N/A	40	Negative News
KLRS Kalaris Therapeutics	4.2798 of 5 stars	$4.81 +1.4%	$15.60 +224.5%	+76.3%	$114.62M	N/A	N/A	110	Analyst Downgrade
AIFC ALT5 Sigma	0.1845 of 5 stars	$0.89 -2.0%	N/A	-90.0%	$113.21M	$24.84M	N/A	170	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYNZ) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mainz Biomed (MYNZ) Competitors

MYNZ vs. EQ, CYPH, KLRS, AIFC, and RANI

How does Mainz Biomed compare to Equillium?

Summary

How does Mainz Biomed compare to Cypherpunk Technologies?

Summary

How does Mainz Biomed compare to Kalaris Therapeutics?

Summary

How does Mainz Biomed compare to ALT5 Sigma?

Summary

How does Mainz Biomed compare to Rani Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mainz Biomed (MYNZ) Competitors

MYNZ vs. EQ, CYPH, KLRS, AIFC, and RANI

How does Mainz Biomed compare to Equillium?

Which has preferable valuation & earnings, EQ or MYNZ?

Which has more risk & volatility, EQ or MYNZ?

Is EQ or MYNZ more profitable?

Do analysts rate EQ or MYNZ?

Does the media prefer EQ or MYNZ?

Do institutionals & insiders have more ownership in EQ or MYNZ?

Summary

How does Mainz Biomed compare to Cypherpunk Technologies?

Does the media favor CYPH or MYNZ?

Do insiders & institutionals have more ownership in CYPH or MYNZ?

Which has more volatility and risk, CYPH or MYNZ?

Do analysts prefer CYPH or MYNZ?

Which has better earnings & valuation, CYPH or MYNZ?

Is CYPH or MYNZ more profitable?

Summary

How does Mainz Biomed compare to Kalaris Therapeutics?

Does the media prefer KLRS or MYNZ?

Which has more risk & volatility, KLRS or MYNZ?

Do insiders and institutionals hold more shares of KLRS or MYNZ?

Do analysts prefer KLRS or MYNZ?

Which has stronger earnings and valuation, KLRS or MYNZ?

Is KLRS or MYNZ more profitable?

Summary

How does Mainz Biomed compare to ALT5 Sigma?

Which has more risk and volatility, MYNZ or AIFC?

Do analysts prefer MYNZ or AIFC?

Which has preferable earnings and valuation, MYNZ or AIFC?

Is MYNZ or AIFC more profitable?

Does the media refer more to MYNZ or AIFC?

Do insiders & institutionals have more ownership in MYNZ or AIFC?

Summary

How does Mainz Biomed compare to Rani Therapeutics?

Is MYNZ or RANI more profitable?

Does the media prefer MYNZ or RANI?

Which has better earnings and valuation, MYNZ or RANI?

Do analysts recommend MYNZ or RANI?

Which has more volatility & risk, MYNZ or RANI?

Do institutionals and insiders hold more shares of MYNZ or RANI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools